Exact Sciences Stock (NASDAQ:EXAS)


ForecastChart

Previous Close

$57.75

52W Range

$38.81 - $72.83

50D Avg

$50.21

200D Avg

$50.95

Market Cap

$11.23B

Avg Vol (3M)

$2.94M

Beta

1.24

Div Yield

-

EXAS Company Profile


Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6,900

IPO Date

Feb 01, 2001

Website

EXAS Performance


Latest Earnings Call Transcripts


Q2 22Aug 02, 22 | 7:16 PM
Q1 22Apr 26, 22 | 9:34 PM
Q4 21Feb 22, 22 | 9:50 PM

Peer Comparison


TickerCompany
GHGuardant Health, Inc.
TWSTTwist Bioscience Corporation
PACBPacific Biosciences of California, Inc.
NTLAIntellia Therapeutics, Inc.
CRSPCRISPR Therapeutics AG
ILMNIllumina, Inc.
NTRANatera, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks